AstraZeneca to acquire US biotech firm TeneoTwo for up to $1.27bn
UK-based pharma giant AstraZeneca has signed a deal worth up to $1.27 billion to acquire American biotech company TeneoTwo in a move to bolster its haematological cancer pipeline. The acquisition includes TNB-486, a CD19/CD3 T-cell engager in phase 1 clinical-stage development. Presently, TNB-486 is being assessed in relapsed and refractory B-cell non-Hodgkin lymphoma. According to […]